Suvorexant + Placebo
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postoperative Insomnia
Conditions
Postoperative Insomnia, Postoperative Delirium
Trial Timeline
May 1, 2023 → May 1, 2025
NCT ID
NCT05823844About Suvorexant + Placebo
Suvorexant + Placebo is a approved stage product being developed by Merck for Postoperative Insomnia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05823844. Target conditions include Postoperative Insomnia, Postoperative Delirium.
What happened to similar drugs?
20 of 20 similar drugs in Postoperative Insomnia were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06655883 | Phase 3 | Recruiting |
| NCT05823844 | Approved | Recruiting |
| NCT04571944 | Phase 3 | Completed |
| NCT03110315 | Approved | Completed |
| NCT02750306 | Phase 3 | Completed |
| NCT02729714 | Approved | Completed |
| NCT02491788 | Approved | Completed |
| NCT02527564 | Approved | Completed |
| NCT01293006 | Phase 1 | Completed |
Competing Products
20 competing products in Postoperative Insomnia